The most active researchers, institutions, and subtopics in HER2-Positive Breast Cancer, from recent PubMed records. Public authorship only, every figure verifiable by PMID.
Analyzed 597 recent PubMed papers (2021-2026) matching "HER2 positive breast cancer antibody drug conjugate". Source: NLM PubMed. Generated July 2026.
| # | Researcher | Affiliation | Papers |
|---|---|---|---|
| 1 | Curigliano Giuseppe | University of Milan | 20 |
| 2 | Im Seock-Ah | Seoul National University Hospital | 17 |
| 3 | Bardia Aditya | Massachusetts General Hospital Cancer Center | 17 |
| 4 | Cortés Javier | International Breast Cancer Center | 16 |
| 5 | Kim Sung-Bae | University of Ulsan College of Medicine | 12 |
| 6 | Modi Shanu | Memorial Sloan Kettering Cancer Center | 12 |
| 7 | Wang Xiaojia | Zhejiang Cancer Hospital | 12 |
| 8 | Iwata Hiroji | Aichi Cancer Center Hospital | 11 |
| 9 | Tsurutani Junji | Showa University | 11 |
| 10 | Park Yeon Hee | Sungkyunkwan University School of Medicine | 11 |
| 11 | Tarantino Paolo | Dana-Farber Cancer Institute | 11 |
| 12 | Li Wei | The First Hospital of Jilin University | 11 |
| 13 | Xu Binghe | Cancer Hospital | 11 |
| 14 | Yan Min | The Affiliated Cancer Hospital of Zhengzhou University & H | 9 |
| 15 | Zhang Jian | Phase I Clinical Trial Center | 9 |
| 16 | De Laurentiis Michelino | Istituto Nazionale Tumori IRCCS Fondazione G Pascale | 9 |
| 17 | Saura Cristina | Vall d'Hebron University Hospital | 9 |
| 18 | Prat Aleix | University of Barcelona | 9 |
Ranked by recent publication volume; names not yet disambiguated and not citation-weighted. The full brief adds ORCID disambiguation, citation weighting, and clinical-trial investigator data.
HER2 Expression in Squamous Cell Carcinoma of the Vulva: A Systematic Review and Meta-Analysis. (2026) · PMID 42449705
Efficacy evaluation of novel targeted drugs in patients with human epidermal growth factor receptor 2-positive breast cancer: A me (2026) · PMID 42447291
A pneumolysin mutant (ΔA146 ply) induces pyroptosis in triple-negative and HER2-positive breast cancer cells via the Caspase-1/GSD (2026) · PMID 42445432
Duocarmycin-Bearing Antibody-Mimetic Drug Conjugate Combined With an ATR Inhibitor Results in Complete Tumor Regression in a KPL-4 (2026) · PMID 42410700
HER2-low as a unique subgroup in breast cancer: insights from neoadjuvant chemotherapy response and survival analysis. (2026) · PMID 42409624
A full HER2-Positive Breast Cancer brief adds citation weighting, name disambiguation, clinical-trial investigators, and a cited PDF, scoped to your exact molecule, competitor set, or region.